Abstract
Next generation sequencing can identify novel gene expression patterns in disease. Beyond differentially expressed genes analysis, we investigated the ability of within-population diversity (α-diversity) of the transcriptome to reveal new biological information in alcohol-related liver disease (ALD), comparing Differential Shannon diversity (DSD) to transcriptome heterogeneity changes. RNA sequencing data from normal livers and patients with early silent ALD and severe AH were analyzed. α-diversity indices and Percent Shannon Diversity of a gene, which refers to this gene’s contribution to total Shannon entropy were calculated. Ingenuity pathway analysis identified canonical pathways determined by differentially expressed genes (DEG) and DSD approaches. ALD significantly decreased hepatic transcriptome α-diversity correlating with increased relative contribution of select genes. These changes were driven by lower abundance gene expression loss. DEG and DSD analyses showed overlapping genes and canonical pathways, but DSD also identified novel genes and pathways not highlighted by DEG. Importantly, DSD more effectively identified differences between preclinical ALD and AH severity stages. ALD decreases hepatic transcriptome heterogeneity, favoring pathways associated with organ damage or damage response. Preclinical and clinical ALD led to differential heterogeneity patterns that may provide new disease insights. DSD analysis identified enriched pathways missed by standard DEG analyses, potentially yielding novel insight into disease mechanisms and biomarkers.
Introduction
Alcohol-related liver disease (ALD) represents a significant global health burden, ranging from early silent steatosis to severe alcohol-associated hepatitis (AH). Traditional genomic analysis relies heavily on Differential Gene Expression (DEG), which identifies individual genes with significant fold-changes. However, DEG often overlooks the complex interactions and the overall structural integrity of the transcriptome. This study proposes a paradigm shift, viewing the liver transcriptome as an ecosystem and applying ecological diversity metrics to map disease progression.
Methods and Data Processing
The researchers utilized RNA sequencing data from the InTEAM Consortium, comprising healthy controls (HC, n=10), early silent ALD (ASH, n=11), and severe AH (n=18). To quantify transcriptome complexity, they adapted ecological indices: Shannon Entropy ($H$), Menhinick and Brillouin Indices, and a novel metric termed Percentage Shannon Entropy (PSE).
The core of their approach is Differential Shannon Diversity (DSD), which measures the log2 fold-change of a gene's contribution to total diversity rather than just its raw expression volume. This dual analytical approach allows for a direct comparison between traditional DEG findings and novel diversity-based insights.
Key Insights and Results
The analysis revealed a significant stepwise reduction in hepatic transcriptome α-diversity as disease severity increased (HC > ASH > AH). This "diversity collapse" is primarily driven by the loss of low-abundance gene expression, akin to the loss of rare species in a stressed ecosystem. As diversity decreases, the transcriptome becomes increasingly dominated by a subset of genes associated with inflammation and damage response.
DSD vs. Traditional DEG
DSD analysis successfully identified novel pathways missed by standard DEG. Specifically, DSD was more effective at highlighting fatty acid oxidation and extracellular matrix (ECM) degradation during the transition from preclinical to clinical disease. Furthermore, cellular deconvolution indicated a 19% reduction in hepatocytes and an 84% increase in Kupffer cells in severe AH, reflecting a shift from metabolic function to an inflammatory state. While DEG and DSD overlapped significantly, DSD identified unique genes like the MITF/p300/CBP complex that were not flagged by standard analysis.
Discussion and Future Directions
By treating the transcriptome as an ecosystem, this study provides a new lens through which to view ALD progression. The stepwise decay of diversity indices suggests that α-diversity could serve as a biomarker for disease stratification. While the study is limited by its nature as a secondary analysis and the lack of sex-based variables, it opens the door for future research into whether this diversity signature is universal across different types of organ failure.
Future applications of DSD to single-cell RNA-seq data may further pinpoint which cellular populations are most vulnerable to diversity loss. Ultimately, the integration of ecological metrics into transcriptomics offers a robust framework for identifying biological pathways that traditional methods overlook, potentially leading to the discovery of new therapeutic targets and diagnostic biomarkers.
Summary updated